Interviews explored multifaceted dimensions (e.g., usability) on two EML applications for the 2021 WHO EML–long-acting insulin analogues for diabetes and immune checkpoint inhibitors for lung cancer. The gene discussed is INS; the disease is diabetes mellitus.